# Pemvidutide

Canonical source: https://retacompare.com/encyclopedia/pemvidutide

Balanced 1:1 GLP-1 / glucagon agonism designed to combine satiety with hepatic lipid burning.

Reference facts

Also known asALT-801CategoryGLP-1 & MetabolicMechanism of actionBalanced 1:1 GLP-1 / glucagon agonism designed to combine satiety with hepatic lipid burning.TargetsGLP-1R, GCGRIndications under research or approvedObesity, MASHRegulatory status (reference entry)Investigational (Phase 2)Half-life~6 daysSequenceHSQGTFTSDYSKYLDEKAAKEFVNWLLAGGPSSGAPPPSSequence notesDual GLP-1 / glucagon receptor agonist with proprietary C18 lipid moiety (EuPort technology).Molecular weight (Da)4500Originator / sponsorAltimmuneFirst reported2021
    Primary References

MOMENTUM Phase 2 (Pemvidutide obesity)


    Explore research articles about Pemvidutide


    This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.

## Sources

- MOMENTUM Phase 2 (Pemvidutide obesity): https://clinicaltrials.gov/study/NCT05295875